



Frontiers in Digestive Research and Practice

Name	Su-Hyun Kim
Affiliation	Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang,
Country	South Korea
Major Field	Neurology

Educational Background

1998-2004 M.D., Gachon University of Medicine and Science, South Korea
2007-2009 M.S. in Neurology, Gachon University of Medicine and Science, South Korea
2013-2017 PhD. in Neurology Gachon University of Medicine and Science, South Korea

Professional Experience

2009-2010 Fellowship, Neuromuscular Disorder Division, Department of Neurology Seoul National University Hospital, Korea
2010-2013 Fellowship, Department of Neurology, Research Institute and Hospital of National Cancer Center, South Korea
2013-2017 Visiting doctor, Department of Neurology, Research Institute and Hospital of National Cancer Center, South Korea
2017-Present Doctor, Department of Neurology, Research Institute and Hospital of National Cancer Center, South Korea

Main Scientific Publications

1. Kim SH, Gomes ABAGR, Schindler P, et al. Blood-based biomarkers for identifying disease activity in AQP4-IgG-Positive Neuromyelitis optica spectrum disorder. *JAMA Neurol* 2024 DEC 23.
2. Kim SH, Ahn BC, Lee DE, et al. Blood neurofilament light chain and glial fibrillary acidic protein as promising screening biomarkers for brain metastases in patients with lung cancer, *Int J Mol Sci*, 2024;25:6397.
3. Kim SH, Kim KH, Hyun JW, et al. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. *Front Oncol* 2022;12:942960
4. Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders; A 14-year Real-Life Experience. *Neurol Neuroimmunol& Neuroinflamm* 2022;9(5):e1179
5. Kim SH, Kwak HS, Lee YJ, et al. Evaluation of serum neurofilament light chain and glial fibrillary acidic protein as screening and monitoring biomarkers for brain metastases. *Cancers* 2021; 13(9): 2227
6. Kim SH, Jang HM, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. *Neurol Neuroimmunol Neuroinflamm* 2021;8(2):e947.
7. Kim SH, Choi MK, Park NY, et al. Serum neurofilament light chain levels as biomarker of neuroaxonal injury and severity of oxaliplatin induced peripheral neuropathy. *Sci Rep* 2020;10(1):7995.

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Main Scientific Publications

8. Kim SH, Kim W, Kim JH, et al. A prospective study of chronic oxaliplatin-induced neuropathy in patients with colon cancer: long term outcomes and predictors of severe oxaliplatin-induced neuropathy. *J Clin Neurol* 2018;14:81-89
9. Kim SH, Kwak K, Hyun JW, et al. Diffusion tensor imaging of normal appearing white matter in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. *Eur J Neurol* 2017;24:966-973.
10. Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms of the therapeutic response to rituximab. *JAMA Neurol* 2015;72:989-95.